Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-02.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 82

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 83
Efficacy and safety of oxcarbazepine in epileptic children

Korean Journal of Pediatrics 2008;51(2):162-169.
Published online February 15, 2008.
Efficacy and safety of oxcarbazepine in epileptic children
Hye Kyung Shin1, Yoon Lee1, Jee-Yeon Lee2, Wooksun Choi1, So-Hee Eun1, Baik-Lin Eun1, Young Sook Hong1, Joo Won Lee1
1Department of Pediatrics, Korea University College of Medicine, Seoul, Korea
2Department of Pediatrics, Kwangmyung-Sungae Hospital, Kwangmyung, Seoul, Korea
소아 간질 환자에서 oxcarbazepine의 효용성과 안전성
신혜경1, 이윤1, 이지연2, 최욱선1, 은소희1, 은백린1, 홍영숙1, 이주원1
1고려대학교 의과대학 소아과학교실
2광명성애병원 소아청소년과
Baik-Lin Eun, Email: bleun@korea.ac.kr
: Oxcabarzepine (OXC), newly recommended antiepileptic drug, has been prescribed for patients with partial seizures and generalized tonic clonic seizures in Korea from 1999. There are limited reports about an efficacy of OXC therapy in epileptic children in Korea. This study evaluated the efficacy and safety of OXC in the light of our experience.
: The patients, who had visited the pediatric neurology clinic of Korea University Guro Hospital from January 2001 to December 2006, were included. The data of 144 patients who were administrated OXC as monotherapy or polytherapy, was summarized retrospectively and we evaluated the efficacy and safety of OXC.
: After 6 months of OXC therapy, 77 patients (53.5%, n=144) achieved seizure freedom, 48 patients (33.3%) experienced >50% improvement. After 12 months of OXC therapy, cessation of seizure was observed in 88 patients (61.1%, n=133), and 27 patients (18.8%) manifested an improvement. Monotherapy group showed superior efficacy to polytherapy one. The frequent side effects of OXC were drowsiness (20.1%), headache (12.5%), dizziness (9.7%) and rash (8.3%). They did not related to patient's age or sex, and dosage of OXC. Twenty four patients (16.7%) experienced hyponatremia, but which were neither symptomatic nor significant one.
: The efficacy and safety of OXC in our patients were excellent and had less significant side effects than established international one. We expect this report contributes toward OXC therapy in epileptic children.
Key Words: Oxcarbazepine, Efficacy, Safety, Child

METRICS Graph View
  • 2,983 View
  • 9 Download